Click Here to Go Directly to the Story




U.S. EDITION
Full Table of Contents
Cover Story
Up Front
Readers Report
Corrections & Clarifications
Books
Technology & You
Economic Viewpoint
Economic Trends
Business Outlook
News: Analysis & Commentary

In Business This Week
Washington Outlook
International Outlook
Book Excerpt
Marketing
Media
The Corporation
Economics
Government
The Workplace

Sports Business
People
Legal Affairs
Information Technology
Finance
Science & Technology
Developments to Watch
BusinessWeek Investor
BusinessWeek Lifestyle
The Barker Portfolio

Inside Wall Street
Figures of the Week
Editorials


INTERNATIONAL EDITIONS
International -- Int'l Cover Story
International -- Readers Report
International -- Corrections & Clarifications
International -- Asian Business
International -- European Business
International -- Int'l Figures of the Week




OCTOBER 14, 2002

International -- Readers Report


  STORY TOOLS
Printer-Friendly Version
E-Mail This Story

On This Page
The Only Cure for Drugmakers' Ills Is Innovation

Calling India to the Negotiating Table

Jordan Is in No Danger of Becoming a Palestinian State


The Only Cure for Drugmakers' Ills Is Innovation

High drug prices have a lot more to do with the way health care is financed in the U.S. than with the role of the Food & Drug Administration ("Get the FDA out of the way, and drug prices will drop," Economic Viewpoint, Sept. 16). Over the past 10 years, we have seen very few new therapeutic options for the major chronic diseases, such as hypertension, high cholesterol, and diabetes. The close-to-$800-million price tag for clinical trials [is the cost of demonstrating] that a "me-too" drug is slightly better than its predecessor.

Pharmaceutical companies are moving research and development to the U.S. because of its academic-industrial complex and entrepreneurial culture. If other regions could offer such a depth of scientific resources and support from generous public institutions such as the National Institutes of Health, the pharmaceutical industry would do its R&D offshore and simply import its products to lucrative markets such as the U.S.

Leonard Lerer
INSEAD
Fontainebleau, France


Back to Top

Calling India to the Negotiating Table

Re: "A whiff of hope" (Asian Business, Sept. 23): I would like to ask Indian intellectuals and saner elements there what India has achieved by positioning almost a million troops in a threatening posture on the borders of Pakistan? Did it help the Bharatiya Janata Party win elections in Uttar Pardesh or elsewhere? Has cross-border terrorism, as they call it, ceased in Kashmir? Has Pakistan yielded any concessions to India? Has it helped India promote its case for fighting terrorism? Has it done any good to India, causing colossal military expenditures and denying Air India routes over Pakistan?

The fallout of this senseless act has hurt India's economy and its place in world opinion. Pakistan, on the other hand, has played its cards admirably and has cashed in on Indian belligerence to maximum advantage.

It is time that India's leadership realized its folly and came to the negotiating table for talks with Pakistan.

Colonel Riaz Jafri (Retired)
Rawalpindi, Pakistan


Back to Top

Jordan Is in No Danger of Becoming a Palestinian State

Contrary to "Why Jordan is terrified of a U.S. attack on Iraq" (International Outlook, Sept. 23), Jordan has been through this before and survived. We have had massive inflows of refugees in 1948, 1967, and in 1990-91. Since the Persian Gulf War, Jordan has adapted and integrated itself into the new world economy and is a member of the U.S.-Jordan Free Trade Agreement.

Even though a war would cause problems and delays to Jordan's economic growth, Jordan's populace and leadership would survive. Your writers, based in Washington and Jerusalem, say that Jordan "could become a de facto Palestinian state." Don't worry--this won't come true.

Kim Faud Abujaber
Amman, Jordan




Back to Top


TODAY'S MOST POPULAR STORIES

  1. America's Best Place to Raise Your Kids
  2. These Men Could Kill SarbOx
  3. This Year's Holiday Hit Toy: Zhu Zhu Pets
  4. Wall Street Plays Hardball
  5. Abercrombie & Fitch Bargains for a Rebound

Get Free RSS Feed >>
  MARKET INFO
DJIA 10318.16 -14.28
S&P 500 1091.38 -3.52
Nasdaq 2146.04 -10.78

Portfolio Service Update

Stock Lookup

Enter name or ticker



Media Kit | Special Sections | MarketPlace | Knowledge Centers
McGraw-Hill Cos.